I think you are way off here Dew. By everything I can see, the Enanta product is far superior to the Pfizer product. Enanta may have to partner in order to get the regulatory access they need to streamline approval but they should be able to do that on very favorable terms. If Pfizer results (which are from an interim analysis) hold up, you can forget Merck or Roche, the contest is between Enanta and Pfizer. Yes, Enanta needs to get into the clinic, but small molecule trials on a therapeutic are much easier to conduct than RCTs on vaccines. The Phase 1 Enanta is planning is on 75 healthy volunteers, how hard should that be to enroll?